<DOC>
	<DOC>NCT01455883</DOC>
	<brief_summary>Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>HbA1c between 7.5% 10.5% on metformin monotherapy BMI between 25 &amp; 45 kg/m2 on thiazolidinedione, sulfonylureas, DPP4, exenatide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months history of pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>